Title(s):
Professor of Urology
Professor of Oncology
Professor of Pathology
Professor of Oncology
Professor of Pathology
David Hall McConnell Professor and Chair of Urology
Urologist -in-Chief, Department of Urology, Oncology
Urologist -in-Chief, Department of Urology, Oncology
Appointment Phone:
410-955-6100
Primary Location:
Johns Hopkins Outpatient Center
Expertise:
Benign Prostatic Hyperplasia, Prostate Cancer, Urology, Urology / Urologic Surgery, Urology, Adult
Education and Experience
Training
- Johns Hopkins University School of Medicine (Baltimore MD)/ (1989)
Residencies
- The Johns Hopkins Hospital (Baltimore MD)/ Urology (1995)
- The Johns Hopkins Hospital (Baltimore MD)/ Surgery (1991)
Certifications
- Urology, American Board of Urology (2007)
Locations
Johns Hopkins Outpatient Center
601 N. Caroline Street
Baltimore, MD 21287
Phone: 410-614-4876
Appointment Phone: 410-955-6100
Fax: 410-955-0833
Location Map
The Johns Hopkins Hospital
600 N. Wolfe Street
Hospital Main Entrance - Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-614-4876
Appointment Phone: 410-955-6100
Fax: 410-955-0833
Location Map
Department / Division
- Urology
Centers/Institutes
Centers / Institutes
- Brady Urological Institute
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
Alan W.Partin M.D., Ph.D. has both basic science and clinical interest in prognosis prediction for men with prostate cancer. Dr. Partin''s laboratories and clinical and surgical interest are focused on development and testing of new and existing methods for predicting the aggressiveness of prostate cancers so that rational treatment decisions can be made by both patients and physicians. Dr. Partin''s laboratories have investigated many new serum tests, some of which are soon to become available for the diagnosis of prostate cancer as well as basics science investigation of new proteins, which may help in detection, and staging of prostate cancer. In addition, Dr. Partin has an academic and clinical interest in treatment of benign prostatic hyperplasia with an emphasis on minimally invasive techniques for treatment of this common disease of men.
Physician Title
David Hall McConnell Professor and Chair of Urology
Urologist -in-Chief, Department of Urology, Oncology
Urologist -in-Chief, Department of Urology, Oncology
Awards and Honors
Journal Citations continued:
Loeb, S.; Partin, A.W. Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention. Rev Urol. 2009 Spring;11(2):114-115.
Loeb, S.; Partin, A.W. Randomized trials of prostate cancer screening. Rev Urol. 2009 Summer;11(3):179-180.
Makarov, D.V.; Isharwal, S.; Sokoll, L.J.; Landis, P.; Marlow, C.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res. 2009 Dec 1;15(23):7316-7321.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for prostate cancer. Annual review of medicine. 2009;60:139-151.
Mozer, P.C.; Partin, A.W.; Stoianovici, D. Robotic image-guided needle interventions of the prostate. Rev Urol. 2009 Winter;11(1):7-15.
Rosenzweig, C.N., Zhang, Z., Sun, X., Sokoll, L.J., Osborne, K., Partin, A.W., and Chan, D.W. Predicition of biochemcial recurrence of prostate cancer using a panel of serum proteomic biomarkers. J Urol. 2009;181(3):1407-1414.
Rosenzweig, C.N.; Zhang, Z.; Sun, X.; Sokoll, L.J.; Osborne, K.; Partin, A.W.; Chan, D.W. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009 Mar;181(3):1407-1414.
Tosoian, J.J.; Loeb, S.; Kettermann, A.; Landis, P.; Elliot, D.J.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Sokoll, L.J. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol. 2009 Dec 12.
Loeb, S.; Partin, A.W. Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention. Rev Urol. 2009 Spring;11(2):114-115.
Loeb, S.; Partin, A.W. Randomized trials of prostate cancer screening. Rev Urol. 2009 Summer;11(3):179-180.
Makarov, D.V.; Isharwal, S.; Sokoll, L.J.; Landis, P.; Marlow, C.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res. 2009 Dec 1;15(23):7316-7321.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for prostate cancer. Annual review of medicine. 2009;60:139-151.
Mozer, P.C.; Partin, A.W.; Stoianovici, D. Robotic image-guided needle interventions of the prostate. Rev Urol. 2009 Winter;11(1):7-15.
Rosenzweig, C.N., Zhang, Z., Sun, X., Sokoll, L.J., Osborne, K., Partin, A.W., and Chan, D.W. Predicition of biochemcial recurrence of prostate cancer using a panel of serum proteomic biomarkers. J Urol. 2009;181(3):1407-1414.
Rosenzweig, C.N.; Zhang, Z.; Sun, X.; Sokoll, L.J.; Osborne, K.; Partin, A.W.; Chan, D.W. Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. J Urol. 2009 Mar;181(3):1407-1414.
Tosoian, J.J.; Loeb, S.; Kettermann, A.; Landis, P.; Elliot, D.J.; Epstein, J.I.; Partin, A.W.; Carter, H.B.; Sokoll, L.J. Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. J Urol. 2009 Dec 12.
Expertise
- Benign Prostatic Hyperplasia
- Prostate Cancer
- Urology
- Urology / Urologic Surgery
- Urology, Adult
Research
Research and Publications
Journal Citations
Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.; Denmeade, S.R. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biol Ther. 2007 Jun 5;6(9).
Duggan, D.; Zheng, S.L.; Knowlton, M.; Benitez, D.; Dimitrov, L.; Wiklund, F.; Robbins, C.; Isaacs, S.D.; Cheng, Y.; Li, G.; Sun, J.; Chang, B.L.; Marovich, L.; Wiley, K.E.; Balter, K.; Stattin, P.; Adami, H.O.; Gielzak, M.; Yan, G.; Sauvageot, J.; Liu, W.; Kim, J.W.; Bleecker, E.R.; Meyers, D.A.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Isaacs, W.B.; Gronberg, H.; Xu, J.; Carpten, J.D. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst. 2007 Dec 19;99(24):1836-1844.
Freedland, S.J.; Humphreys, E.B.; Mangold, L.A.; Eisenberger, M.; Dorey, F.J.; Walsh, P.C.; Partin, A.W. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007 May 1;25(13):1765-1771.
Freedland, S.J.; Partin, A.W.; Humphreys, E.B.; Mangold, L.A.; Walsh, P.C. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007 Apr 1;109(7):1273-1278.
Gudmundsson, J.; Sulem, P.; Manolescu, A.; Amundadottir, L.T.; Gudbjartsson, D.; Helgason, A.; Rafnar, T.; Bergthorsson, J.T.; Agnarsson, B.A.; Baker, A.; Sigurdsson, A.; Benediktsdottir, K.R.; Jakobsdottir, M.; Xu, J.; Blondal, T.; Kostic, J.; Sun, J.; Ghosh, S.; Stacey, S.N.; Mouy, M.; Saemundsdottir, J.; Backman, V.M.; Kristjansson, K.; Tres, A.; Partin, A.W.; Albers-Akkers, M.T.; Godino-Ivan Marcos, J.; Walsh, P.C.; Swinkels, D.W.; Navarrete, S.; Isaacs, S.D.; Aben, K.K.; Graif, T.; Cashy, J.; Ruiz-Echarri, M.; Wiley, K.E.; Suarez, B.K.; Witjes, J.A.; Frigge, M.; Ober, C.; Jonsson, E.; Einarsson, G.V.; Mayordomo, J.I.; Kiemeney, L.A.; Isaacs, W.B.; Catalona, W.J.; Barkardottir, R.B.; Gulcher, J.R.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007 May;39(5):631-637.
Hansel, D.E.; DeMarzo, A.M.; Platz, E.A.; Jadallah, S.; Hicks, J.; Epstein, J.I.; Partin, A.W.; Netto, G.J. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol. 2007 May;177(5):1736-1740.
Hernandez, D.J.; Nielsen, M.E.; Han, M.; Partin, A.W. Contemporary evaluation of the D''amico risk classification of prostate cancer. Urology. 2007 Nov;70(5):931-935.
Kibel, A.S.; Rosenbaum, E.; Kattan, M.W.; Picus, J.; Dreicer, R.; Klein, E.A.; Chatta, G.S.; Nelson, J.B.; DiPaola, R.S.; Roth, B.J.; Cookson, M.S.; Wilding, G.; Jarrard, D.F.; Beer, T.M.; Ryan, C.W.; Petrylak, D.P.; Benson, M.C.; Partin, A.W.; Garrett-Mayer, E.; Eisenberger, M.A. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May;177(5):1777-1781.
Leman, E.S.; Cannon, G.W.; Trock, B.J.; Sokoll, L.J.; Chan, D.W.; Mangold, L.; Partin, A.W.; Getzenberg, R.H. EPCA-2: a highly specific serum marker for prostate cancer. Urology. 2007 Apr;69(4):714-720.
Makarov, D.V.; Partin, A.W. Prostate-Cancer Risk Stratification via Early PSA Testing. Rev Urol. 2007 Spring;9(2):91-92.
Makarov, D.V.; Partin, A.W. Postprostatectomy risk stratification based on detection of occult lymph node metastasis. Rev Urol. 2007 Winter;9(1):41-43.
Makarov, D.V.; Trock, B.J.; Humphreys, E.B.; Mangold, L.A.; Walsh, P.C.; Epstein, J.I.; Partin, A.W. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007 Jun;69(6):1095-1101.
Malik, G.; Rojahn, E.; Ward, M.D.; Gretzer, M.B.; Partin, A.W.; Semmes, O.J.; Veltri, R.W. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression. Prostate. 2007 Oct 1;67(14):1565-1575.
Mavropoulos, J.C.; Partin, A.W.; Amling, C.L.; Terris, M.K.; Kane, C.J.; Aronson, W.J.; Presti, J.C., Jr.; Mangold, L.A.; Freedland, S.J. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007 Jun;69(6):1138-1142.
Nielsen, M.E.; Partin, A.W. The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol. 2007 Spring;9(2):57-62.
Parsons, J.K.; Partin, A.W.; Trock, B.; Bruzek, D.J.; Cheli, C.; Sokoll, L.J. Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy. BJU Int. 2007 Apr;99(4):758-761.
Shafer, M.W.; Mangold, L.; Partin, A.W.; Haab, B.B. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease. Prostate. 2007 Feb 15;67(3):255-267.
Veltri, R.W.; Marlow, C.; Khan, M.A.; Miller, M.C.; Epstein, J.I.; Partin, A.W. Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate. 2007 Aug 1;67(11):1202-1210.
Zheng, S.L.; Sun, J.; Cheng, Y.; Li, G.; Hsu, F.C.; Zhu, Y.; Chang, B.L.; Liu, W.; Kim, J.W.; Turner, A.R.; Gielzak, M.; Yan, G.; Isaacs, S.D.; Wiley, K.E.; Sauvageot, J.; Chen, H.S.; Gurganus, R.; Mangold, L.A.; Trock, B.J.; Gronberg, H.; Duggan, D.; Carpten, J.D.; Partin, A.W.; Walsh, P.C.; Xu, J.; Isaacs, W.B. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst. 2007 Oct 17;99(20):1525-1533.
Alumkal, J.J.; Zhang, Z.; Humphreys, E.B.; Bennett, C.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Garrett-Mayer, E.; DeMarzo, A.M.; Herman, J.G. Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008 Dec;72(6):1234-1239.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Rogers, C.G.; Lin, X.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008 Feb;179(2):529-534; discussion 534-525.
Deras, I.L.; Aubin, S.M.; Blase, A.; Day, J.R.; Koo, S.; Partin, A.W.; Ellis, W.J.; Marks, L.S.; Fradet, Y.; Rittenhouse, H.; Groskopf, J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008 Apr;179(4):1587-1592.
DeWeese, T.L. Radiation Therapy for Prostate Cancer. In: Wein, K., Novick, Partin, and Peters, editor. Vol. Tenth Edition, Cambell-Walsh Urology: Elsevier Science; 2008. p. In Press.
Gudmundsson, J.; Sulem, P.; Rafnar, T.; Bergthorsson, J.T.; Manolescu, A.; Gudbjartsson, D.; Agnarsson, B.A.; Sigurdsson, A.; Benediktsdottir, K.R.; Blondal, T.; Jakobsdottir, M.; Stacey, S.N.; Kostic, J.; Kristinsson, K.T.; Birgisdottir, B.; Ghosh, S.; Magnusdottir, D.N.; Thorlacius, S.; Thorleifsson, G.; Zheng, S.L.; Sun, J.; Chang, B.L.; Elmore, J.B.; Breyer, J.P.; McReynolds, K.M.; Bradley, K.M.; Yaspan, B.L.; Wiklund, F.; Stattin, P.; Lindstrom, S.; Adami, H.O.; McDonnell, S.K.; Schaid, D.J.; Cunningham, J.M.; Wang, L.; Cerhan, J.R.; St Sauver, J.L.; Isaacs, S.D.; Wiley, K.E.; Partin, A.W.; Walsh, P.C.; Polo, S.; Ruiz-Echarri, M.; Navarrete, S.; Fuertes, F.; Saez, B.; Godino, J.; Weijerman, P.C.; Swinkels, D.W.; Aben, K.K.; Witjes, J.A.; Suarez, B.K.; Helfand, B.T.; Frigge, M.L.; Kristjansson, K.; Ober, C.; Jonsson, E.; Einarsson, G.V.; Xu, J.; Gronberg, H.; Smith, J.R.; Thibodeau, S.N.; Isaacs, W.B.; Catalona, W.J.; Mayordomo, J.I.; Kiemeney, L.A.; Barkardottir, R.B.; Gulcher, J.R.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008 Mar;40(3):281-283.
Hernandez, D.J.; Han, M.; Humphreys, E.B.; Mangold, L.A.; Taneja, S.S.; Childs, S.J.; Bartsch, G.; Partin, A.W. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2008 Oct 24.
Hernandez, D.J.; Nielsen, M.E.; Han, M.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Epstein, J.I. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology. 2008 Jul;72(1):172-176.
Isharwal, S.; Miller, M.C.; Epstein, J.I.; Mangold, L.A.; Humphreys, E.; Partin, A.W.; Veltri, R.W. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer. 2008 Dec 1;123(11):2636-2643.
Isharwal, S.; Miller, M.C.; Marlow, C.; Makarov, D.V.; Partin, A.W.; Veltri, R.W. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate. 2008 Jul 1;68(10):1097-1104.
Loeb, S.; Hernandez, D.J.; Mangold, L.A.; Humphreys, E.B.; Agro, M.; Walsh, P.C.; Partin, A.W.; Han, M. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int. 2008 Jun;101(12):1503-1506.
Loeb, S.; Partin, A.W. Single nucleotide polymorphisms and prostate cancer susceptibility. Rev Urol. 2008 Fall;10(4):304-305.
Magheli, A.; Rais-Bahrami, S.; Trock, B.J.; Humphreys, E.B.; Partin, A.W.; Han, M.; Gonzalgo, M.L. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. J Urol. 2008 May;179(5):1780-1784; discussion 1784.
Magheli, A.; Rais-Bahrami, S.; Trock, B.J.; Humphreys, E.B.; Partin, A.W.; Han, M.; Gonzalgo, M.L. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology. 2008 Dec;72(6):1246-1251.
Makarov, D.V.; Humphreys, E.B.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Eisenberger, M.A.; Walsh, P.C.; Trock, B.J. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008 Jan;179(1):156-161; discussion 161-152.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for Prostate Cancer. Annual review of medicine. 2008 Oct 23.
Makarov, D.V.; Marlow, C.; Epstein, J.I.; Miller, M.C.; Landis, P.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate. 2008 Feb 1;68(2):183-189.
Makarov, D.V.; Partin, A.W. Weighing the risks: prostate cancer versus cardiovascular disease. Rev Urol. 2008 Spring;10(2):171-173.
Makarov, D.V.; Partin, A.W. Focal therapy for prostate cancer. Rev Urol. 2008 Winter;10(1):81-82.
McLerran, D.; Grizzle, W.E.; Feng, Z.; Bigbee, W.L.; Banez, L.L.; Cazares, L.H.; Chan, D.W.; Diaz, J.; Izbicka, E.; Kagan, J.; Malehorn, D.E.; Malik, G.; Oelschlager, D.; Partin, A.; Randolph, T.; Rosenzweig, N.; Srivastava, S.; Srivastava, S.; Thompson, I.M.; Thornquist, M.; Troyer, D.; Yasui, Y.; Zhang, Z.; Zhu, L.; Semmes, O.J. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. Clin Chem. 2008 Jan;54(1):44-52.
McLerran, D.; Grizzle, W.E.; Feng, Z.; Thompson, I.M.; Bigbee, W.L.; Cazares, L.H.; Chan, D.W.; Dahlgren, J.; Diaz, J.; Kagan, J.; Lin, D.W.; Malik, G.; Oelschlager, D.; Partin, A.; Randolph, T.W.; Sokoll, L.; Srivastava, S.; Srivastava, S.; Thornquist, M.; Troyer, D.; Wright, G.L.; Zhang, Z.; Zhu, L.; Semmes, O.J. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clin Chem. 2008 Jan;54(1):53-60.
Muntener, M.; Epstein, J.I.; Hernandez, D.J.; Gonzalgo, M.L.; Mangold, L.; Humphreys, E.; Walsh, P.C.; Partin, A.W.; Nielsen, M.E. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol. 2008 Apr;53(4):767-775; discussion 775-766.
Nielsen, M.E.; Makarov, D.V.; Humphreys, E.; Mangold, L.; Partin, A.W.; Walsh, P.C. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion-"nadir + 2"? Urology. 2008 Aug;72(2):389-393; discussion 394-385.
Sokoll, L.J.; Wang, Y.; Feng, Z.; Kagan, J.; Partin, A.W.; Sanda, M.G.; Thompson, I.M.; Chan, D.W. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008 Aug;180(2):539-543; discussion 543.
Sun, J.; Chang, B.L.; Isaacs, S.D.; Wiley, K.E.; Wiklund, F.; Stattin, P.; Duggan, D.; Carpten, J.D.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Gronberg, H.; Xu, J.; Isaacs, W.B.; Zheng, S.L. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate. 2008 Sep 1;68(12):1257-1262.
Sun, J.; Purcell, L.; Gao, Z.; Isaacs, S.D.; Wiley, K.E.; Hsu, F.C.; Liu, W.; Duggan, D.; Carpten, J.D.; Gronberg, H.; Xu, J.; Chang, B.L.; Partin, A.W.; Walsh, P.C.; Isaacs, W.B.; Zheng, S.L. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate. 2008 May 15;68(7):691-697.
Sun, J.; Zheng, S.L.; Wiklund, F.; Isaacs, S.D.; Purcell, L.D.; Gao, Z.; Hsu, F.C.; Kim, S.T.; Liu, W.; Zhu, Y.; Stattin, P.; Adami, H.O.; Wiley, K.E.; Dimitrov, L.; Sun, J.; Li, T.; Turner, A.R.; Adams, T.S.; Adolfsson, J.; Johansson, J.E.; Lowey, J.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Trent, J.M.; Duggan, D.; Carpten, J.; Chang, B.L.; Gronberg, H.; Isaacs, W.B.; Xu, J. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet. 2008 Oct;40(10):1153-1155.
Trock, B.J.; Han, M.; Freedland, S.J.; Humphreys, E.B.; DeWeese, T.L.; Partin, A.W.; Walsh, P.C. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Jama. 2008 Jun 18;299(23):2760-2769.
Veltri, R.W.; Isharwal, S.; Miller, M.C.; Epstein, J.I.; Mangold, L.A.; Humphreys, E.; Partin, A.W. Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate. 2008 Dec 1;68(16):1806-1815.
Veltri, R.W.; Miller, M.C.; Isharwal, S.; Marlow, C.; Makarov, D.V.; Partin, A.W. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):102-110.
Wu, I.; Nielsen, M.E.; Han, M.; Partin, A.W.; Makarov, D.V. Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival? Urology. 2008 Dec;72(6):1219-1223.
Xu, J.; Isaacs, S.D.; Sun, J.; Li, G.; Wiley, K.E.; Zhu, Y.; Hsu, F.C.; Wiklund, F.; Turner, A.R.; Adams, T.S.; Liu, W.; Trock, B.J.; Partin, A.W.; Chang, B.; Walsh, P.C.; Gronberg, H.; Isaacs, W.; Zheng, S. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res. 2008 Sep 15;14(18):5819-5824.
Yoon, G.S.; Wang, W.; Osunkoya, A.O.; Lane, Z.; Partin, A.W.; Epstein, J.I. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol. 2008 Jun;179(6):2203-2206; discussion 2206.
Zhao, K.H.; Hernandez, D.J.; Han, M.; Humphreys, E.B.; Mangold, L.A.; Partin, A.W. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology. 2008 Aug;72(2):396-400.
Antonarakis, E.S.; Heath, E.I.; Walczak, J.R.; Nelson, W.G.; Fedor, H.; De Marzo, A.M.; Zahurak, M.L.; Piantadosi, S.; Dannenberg, A.J.; Gurganus, R.T.; Baker, S.D.; Parnes, H.L.; DeWeese, T.L.; Partin, A.W.; Carducci, M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-4993.
Banez, L.L.; Sun, L.; Trock, B.J.; Han, M.; Partin, A.W.; Aronson, W.J.; Terris, M.K.; Presti, J.C., Jr.; Kane, C.J.; Amling, C.L.; Moul, J.W.; Freedland, S.J. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug;182(2):491-496; discussion 496-498.
Brawer, M.K.; Loeb, S.; Partin, A.W.; Yoshimura, N.; Chancellor, M.B.; Roehrborn, C.G.; Assimos, D.G.; Nickel, J.C.; Shuch, B.; Pouliot, F.; Belldegrun, A.S.; Shapiro, E. Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring;11(2):82-107.
Chun, F.K.; de la Taille, A.; van Poppel, H.; Marberger, M.; Stenzl, A.; Mulders, P.F.; Huland, H.; Abbou, C.C.; Stillebroer, A.B.; van Gils, M.P.; Schalken, J.A.; Fradet, Y.; Marks, L.S.; Ellis, W.; Partin, A.W.; Haese, A. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009 Oct;56(4):659-667.
Fujita, K.; Ewing, C.M.; Chan, D.Y.; Mangold, L.A.; Partin, A.W.; Isaacs, W.B.; Pavlovich, C.P. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer. 2009 Feb 1;124(3):664-669.
Hernandez, D.J.; Han, M.; Humphreys, E.B.; Mangold, L.A.; Taneja, S.S.; Childs, S.J.; Bartsch, G.; Partin, A.W. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2009 Mar;103(5):609-614.
Hu, R.; Dunn, T.A.; Wei, S.; Isharwal, S.; Veltri, R.W.; Humphreys, E.; Han, M.; Partin, A.W.; Vessella, R.L.; Isaacs, W.B.; Bova, G.S.; Luo, J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009 Jan 1;69(1):16-22.
Isharwal, S.; Miller, M.C.; Epstein, J.I.; Mangold, L.A.; Humphreys, E.; Partin, A.W.; Veltri, R.W. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Urology. 2009 May;73(5):1092-1097.
Jain, A.; McKnight, D.A.; Fisher, L.W.; Humphreys, E.B.; Mangold, L.A.; Partin, A.W.; Fedarko, N.S. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res. 2009 Aug 15;15(16):5199-5207.
Kader, A.K.; Sun, J.; Isaacs, S.D.; Wiley, K.E.; Yan, G.; Kim, S.T.; Fedor, H.; DeMarzo, A.M.; Epstein, J.I.; Walsh, P.C.; Partin, A.W.; Trock, B.; Zheng, S.L.; Xu, J.; Isaacs, W. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009 Aug 1;69(11):1195-1205.
Leman, E.S.; Magheli, A.; Cannon, G.W.; Mangold, L.; Partin, A.W.; Getzenberg, R.H. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate. 2009 Aug 1;69(11):1188-1194.
Collins, C.; Carducci, M.A.; Eisenberger, M.A.; Isaacs, J.T.; Partin, A.W.; Pili, R.; Sinibaldi, V.J.; Walczak, J.S.; Denmeade, S.R. Preclinical and Clinical Studies With the Multi-Kinase Inhibitor CEP-701 as Treatment for Prostate Cancer Demonstrate the Inadequacy of PSA Response as a Primary Endpoint. Cancer Biol Ther. 2007 Jun 5;6(9).
Duggan, D.; Zheng, S.L.; Knowlton, M.; Benitez, D.; Dimitrov, L.; Wiklund, F.; Robbins, C.; Isaacs, S.D.; Cheng, Y.; Li, G.; Sun, J.; Chang, B.L.; Marovich, L.; Wiley, K.E.; Balter, K.; Stattin, P.; Adami, H.O.; Gielzak, M.; Yan, G.; Sauvageot, J.; Liu, W.; Kim, J.W.; Bleecker, E.R.; Meyers, D.A.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Isaacs, W.B.; Gronberg, H.; Xu, J.; Carpten, J.D. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst. 2007 Dec 19;99(24):1836-1844.
Freedland, S.J.; Humphreys, E.B.; Mangold, L.A.; Eisenberger, M.; Dorey, F.J.; Walsh, P.C.; Partin, A.W. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol. 2007 May 1;25(13):1765-1771.
Freedland, S.J.; Partin, A.W.; Humphreys, E.B.; Mangold, L.A.; Walsh, P.C. Radical prostatectomy for clinical stage T3a disease. Cancer. 2007 Apr 1;109(7):1273-1278.
Gudmundsson, J.; Sulem, P.; Manolescu, A.; Amundadottir, L.T.; Gudbjartsson, D.; Helgason, A.; Rafnar, T.; Bergthorsson, J.T.; Agnarsson, B.A.; Baker, A.; Sigurdsson, A.; Benediktsdottir, K.R.; Jakobsdottir, M.; Xu, J.; Blondal, T.; Kostic, J.; Sun, J.; Ghosh, S.; Stacey, S.N.; Mouy, M.; Saemundsdottir, J.; Backman, V.M.; Kristjansson, K.; Tres, A.; Partin, A.W.; Albers-Akkers, M.T.; Godino-Ivan Marcos, J.; Walsh, P.C.; Swinkels, D.W.; Navarrete, S.; Isaacs, S.D.; Aben, K.K.; Graif, T.; Cashy, J.; Ruiz-Echarri, M.; Wiley, K.E.; Suarez, B.K.; Witjes, J.A.; Frigge, M.; Ober, C.; Jonsson, E.; Einarsson, G.V.; Mayordomo, J.I.; Kiemeney, L.A.; Isaacs, W.B.; Catalona, W.J.; Barkardottir, R.B.; Gulcher, J.R.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet. 2007 May;39(5):631-637.
Hansel, D.E.; DeMarzo, A.M.; Platz, E.A.; Jadallah, S.; Hicks, J.; Epstein, J.I.; Partin, A.W.; Netto, G.J. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol. 2007 May;177(5):1736-1740.
Hernandez, D.J.; Nielsen, M.E.; Han, M.; Partin, A.W. Contemporary evaluation of the D''amico risk classification of prostate cancer. Urology. 2007 Nov;70(5):931-935.
Kibel, A.S.; Rosenbaum, E.; Kattan, M.W.; Picus, J.; Dreicer, R.; Klein, E.A.; Chatta, G.S.; Nelson, J.B.; DiPaola, R.S.; Roth, B.J.; Cookson, M.S.; Wilding, G.; Jarrard, D.F.; Beer, T.M.; Ryan, C.W.; Petrylak, D.P.; Benson, M.C.; Partin, A.W.; Garrett-Mayer, E.; Eisenberger, M.A. Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May;177(5):1777-1781.
Leman, E.S.; Cannon, G.W.; Trock, B.J.; Sokoll, L.J.; Chan, D.W.; Mangold, L.; Partin, A.W.; Getzenberg, R.H. EPCA-2: a highly specific serum marker for prostate cancer. Urology. 2007 Apr;69(4):714-720.
Makarov, D.V.; Partin, A.W. Prostate-Cancer Risk Stratification via Early PSA Testing. Rev Urol. 2007 Spring;9(2):91-92.
Makarov, D.V.; Partin, A.W. Postprostatectomy risk stratification based on detection of occult lymph node metastasis. Rev Urol. 2007 Winter;9(1):41-43.
Makarov, D.V.; Trock, B.J.; Humphreys, E.B.; Mangold, L.A.; Walsh, P.C.; Epstein, J.I.; Partin, A.W. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007 Jun;69(6):1095-1101.
Malik, G.; Rojahn, E.; Ward, M.D.; Gretzer, M.B.; Partin, A.W.; Semmes, O.J.; Veltri, R.W. SELDI protein profiling of dunning R-3327 derived cell lines: identification of molecular markers of prostate cancer progression. Prostate. 2007 Oct 1;67(14):1565-1575.
Mavropoulos, J.C.; Partin, A.W.; Amling, C.L.; Terris, M.K.; Kane, C.J.; Aronson, W.J.; Presti, J.C., Jr.; Mangold, L.A.; Freedland, S.J. Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? Urology. 2007 Jun;69(6):1138-1142.
Nielsen, M.E.; Partin, A.W. The impact of definitions of failure on the interpretation of biochemical recurrence following treatment of clinically localized prostate cancer. Rev Urol. 2007 Spring;9(2):57-62.
Parsons, J.K.; Partin, A.W.; Trock, B.; Bruzek, D.J.; Cheli, C.; Sokoll, L.J. Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy. BJU Int. 2007 Apr;99(4):758-761.
Shafer, M.W.; Mangold, L.; Partin, A.W.; Haab, B.B. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease. Prostate. 2007 Feb 15;67(3):255-267.
Veltri, R.W.; Marlow, C.; Khan, M.A.; Miller, M.C.; Epstein, J.I.; Partin, A.W. Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. Prostate. 2007 Aug 1;67(11):1202-1210.
Zheng, S.L.; Sun, J.; Cheng, Y.; Li, G.; Hsu, F.C.; Zhu, Y.; Chang, B.L.; Liu, W.; Kim, J.W.; Turner, A.R.; Gielzak, M.; Yan, G.; Isaacs, S.D.; Wiley, K.E.; Sauvageot, J.; Chen, H.S.; Gurganus, R.; Mangold, L.A.; Trock, B.J.; Gronberg, H.; Duggan, D.; Carpten, J.D.; Partin, A.W.; Walsh, P.C.; Xu, J.; Isaacs, W.B. Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst. 2007 Oct 17;99(20):1525-1533.
Alumkal, J.J.; Zhang, Z.; Humphreys, E.B.; Bennett, C.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Garrett-Mayer, E.; DeMarzo, A.M.; Herman, J.G. Effect of DNA methylation on identification of aggressive prostate cancer. Urology. 2008 Dec;72(6):1234-1239.
Bastian, P.J.; Palapattu, G.S.; Yegnasubramanian, S.; Rogers, C.G.; Lin, X.; Mangold, L.A.; Trock, B.; Eisenberger, M.A.; Partin, A.W.; Nelson, W.G. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008 Feb;179(2):529-534; discussion 534-525.
Deras, I.L.; Aubin, S.M.; Blase, A.; Day, J.R.; Koo, S.; Partin, A.W.; Ellis, W.J.; Marks, L.S.; Fradet, Y.; Rittenhouse, H.; Groskopf, J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008 Apr;179(4):1587-1592.
DeWeese, T.L. Radiation Therapy for Prostate Cancer. In: Wein, K., Novick, Partin, and Peters, editor. Vol. Tenth Edition, Cambell-Walsh Urology: Elsevier Science; 2008. p. In Press.
Gudmundsson, J.; Sulem, P.; Rafnar, T.; Bergthorsson, J.T.; Manolescu, A.; Gudbjartsson, D.; Agnarsson, B.A.; Sigurdsson, A.; Benediktsdottir, K.R.; Blondal, T.; Jakobsdottir, M.; Stacey, S.N.; Kostic, J.; Kristinsson, K.T.; Birgisdottir, B.; Ghosh, S.; Magnusdottir, D.N.; Thorlacius, S.; Thorleifsson, G.; Zheng, S.L.; Sun, J.; Chang, B.L.; Elmore, J.B.; Breyer, J.P.; McReynolds, K.M.; Bradley, K.M.; Yaspan, B.L.; Wiklund, F.; Stattin, P.; Lindstrom, S.; Adami, H.O.; McDonnell, S.K.; Schaid, D.J.; Cunningham, J.M.; Wang, L.; Cerhan, J.R.; St Sauver, J.L.; Isaacs, S.D.; Wiley, K.E.; Partin, A.W.; Walsh, P.C.; Polo, S.; Ruiz-Echarri, M.; Navarrete, S.; Fuertes, F.; Saez, B.; Godino, J.; Weijerman, P.C.; Swinkels, D.W.; Aben, K.K.; Witjes, J.A.; Suarez, B.K.; Helfand, B.T.; Frigge, M.L.; Kristjansson, K.; Ober, C.; Jonsson, E.; Einarsson, G.V.; Xu, J.; Gronberg, H.; Smith, J.R.; Thibodeau, S.N.; Isaacs, W.B.; Catalona, W.J.; Mayordomo, J.I.; Kiemeney, L.A.; Barkardottir, R.B.; Gulcher, J.R.; Thorsteinsdottir, U.; Kong, A.; Stefansson, K. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet. 2008 Mar;40(3):281-283.
Hernandez, D.J.; Han, M.; Humphreys, E.B.; Mangold, L.A.; Taneja, S.S.; Childs, S.J.; Bartsch, G.; Partin, A.W. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2008 Oct 24.
Hernandez, D.J.; Nielsen, M.E.; Han, M.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Epstein, J.I. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology. 2008 Jul;72(1):172-176.
Isharwal, S.; Miller, M.C.; Epstein, J.I.; Mangold, L.A.; Humphreys, E.; Partin, A.W.; Veltri, R.W. Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer. 2008 Dec 1;123(11):2636-2643.
Isharwal, S.; Miller, M.C.; Marlow, C.; Makarov, D.V.; Partin, A.W.; Veltri, R.W. p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate. 2008 Jul 1;68(10):1097-1104.
Loeb, S.; Hernandez, D.J.; Mangold, L.A.; Humphreys, E.B.; Agro, M.; Walsh, P.C.; Partin, A.W.; Han, M. Progression after radical prostatectomy for men in their thirties compared to older men. BJU Int. 2008 Jun;101(12):1503-1506.
Loeb, S.; Partin, A.W. Single nucleotide polymorphisms and prostate cancer susceptibility. Rev Urol. 2008 Fall;10(4):304-305.
Magheli, A.; Rais-Bahrami, S.; Trock, B.J.; Humphreys, E.B.; Partin, A.W.; Han, M.; Gonzalgo, M.L. Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy. J Urol. 2008 May;179(5):1780-1784; discussion 1784.
Magheli, A.; Rais-Bahrami, S.; Trock, B.J.; Humphreys, E.B.; Partin, A.W.; Han, M.; Gonzalgo, M.L. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology. 2008 Dec;72(6):1246-1251.
Makarov, D.V.; Humphreys, E.B.; Mangold, L.A.; Carducci, M.A.; Partin, A.W.; Eisenberger, M.A.; Walsh, P.C.; Trock, B.J. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol. 2008 Jan;179(1):156-161; discussion 161-152.
Makarov, D.V.; Loeb, S.; Getzenberg, R.H.; Partin, A.W. Biomarkers for Prostate Cancer. Annual review of medicine. 2008 Oct 23.
Makarov, D.V.; Marlow, C.; Epstein, J.I.; Miller, M.C.; Landis, P.; Partin, A.W.; Carter, H.B.; Veltri, R.W. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. Prostate. 2008 Feb 1;68(2):183-189.
Makarov, D.V.; Partin, A.W. Weighing the risks: prostate cancer versus cardiovascular disease. Rev Urol. 2008 Spring;10(2):171-173.
Makarov, D.V.; Partin, A.W. Focal therapy for prostate cancer. Rev Urol. 2008 Winter;10(1):81-82.
McLerran, D.; Grizzle, W.E.; Feng, Z.; Bigbee, W.L.; Banez, L.L.; Cazares, L.H.; Chan, D.W.; Diaz, J.; Izbicka, E.; Kagan, J.; Malehorn, D.E.; Malik, G.; Oelschlager, D.; Partin, A.; Randolph, T.; Rosenzweig, N.; Srivastava, S.; Srivastava, S.; Thompson, I.M.; Thornquist, M.; Troyer, D.; Yasui, Y.; Zhang, Z.; Zhu, L.; Semmes, O.J. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. Clin Chem. 2008 Jan;54(1):44-52.
McLerran, D.; Grizzle, W.E.; Feng, Z.; Thompson, I.M.; Bigbee, W.L.; Cazares, L.H.; Chan, D.W.; Dahlgren, J.; Diaz, J.; Kagan, J.; Lin, D.W.; Malik, G.; Oelschlager, D.; Partin, A.; Randolph, T.W.; Sokoll, L.; Srivastava, S.; Srivastava, S.; Thornquist, M.; Troyer, D.; Wright, G.L.; Zhang, Z.; Zhu, L.; Semmes, O.J. SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. Clin Chem. 2008 Jan;54(1):53-60.
Muntener, M.; Epstein, J.I.; Hernandez, D.J.; Gonzalgo, M.L.; Mangold, L.; Humphreys, E.; Walsh, P.C.; Partin, A.W.; Nielsen, M.E. Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol. 2008 Apr;53(4):767-775; discussion 775-766.
Nielsen, M.E.; Makarov, D.V.; Humphreys, E.; Mangold, L.; Partin, A.W.; Walsh, P.C. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion-"nadir + 2"? Urology. 2008 Aug;72(2):389-393; discussion 394-385.
Sokoll, L.J.; Wang, Y.; Feng, Z.; Kagan, J.; Partin, A.W.; Sanda, M.G.; Thompson, I.M.; Chan, D.W. [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol. 2008 Aug;180(2):539-543; discussion 543.
Sun, J.; Chang, B.L.; Isaacs, S.D.; Wiley, K.E.; Wiklund, F.; Stattin, P.; Duggan, D.; Carpten, J.D.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Gronberg, H.; Xu, J.; Isaacs, W.B.; Zheng, S.L. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate. 2008 Sep 1;68(12):1257-1262.
Sun, J.; Purcell, L.; Gao, Z.; Isaacs, S.D.; Wiley, K.E.; Hsu, F.C.; Liu, W.; Duggan, D.; Carpten, J.D.; Gronberg, H.; Xu, J.; Chang, B.L.; Partin, A.W.; Walsh, P.C.; Isaacs, W.B.; Zheng, S.L. Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate. 2008 May 15;68(7):691-697.
Sun, J.; Zheng, S.L.; Wiklund, F.; Isaacs, S.D.; Purcell, L.D.; Gao, Z.; Hsu, F.C.; Kim, S.T.; Liu, W.; Zhu, Y.; Stattin, P.; Adami, H.O.; Wiley, K.E.; Dimitrov, L.; Sun, J.; Li, T.; Turner, A.R.; Adams, T.S.; Adolfsson, J.; Johansson, J.E.; Lowey, J.; Trock, B.J.; Partin, A.W.; Walsh, P.C.; Trent, J.M.; Duggan, D.; Carpten, J.; Chang, B.L.; Gronberg, H.; Isaacs, W.B.; Xu, J. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet. 2008 Oct;40(10):1153-1155.
Trock, B.J.; Han, M.; Freedland, S.J.; Humphreys, E.B.; DeWeese, T.L.; Partin, A.W.; Walsh, P.C. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. Jama. 2008 Jun 18;299(23):2760-2769.
Veltri, R.W.; Isharwal, S.; Miller, M.C.; Epstein, J.I.; Mangold, L.A.; Humphreys, E.; Partin, A.W. Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate. 2008 Dec 1;68(16):1806-1815.
Veltri, R.W.; Miller, M.C.; Isharwal, S.; Marlow, C.; Makarov, D.V.; Partin, A.W. Prediction of prostate-specific antigen recurrence in men with long-term follow-up postprostatectomy using quantitative nuclear morphometry. Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):102-110.
Wu, I.; Nielsen, M.E.; Han, M.; Partin, A.W.; Makarov, D.V. Does laterality of positive needle biopsy in clinical T2a patients with prostate cancer affect biochemical recurrence-free survival? Urology. 2008 Dec;72(6):1219-1223.
Xu, J.; Isaacs, S.D.; Sun, J.; Li, G.; Wiley, K.E.; Zhu, Y.; Hsu, F.C.; Wiklund, F.; Turner, A.R.; Adams, T.S.; Liu, W.; Trock, B.J.; Partin, A.W.; Chang, B.; Walsh, P.C.; Gronberg, H.; Isaacs, W.; Zheng, S. Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res. 2008 Sep 15;14(18):5819-5824.
Yoon, G.S.; Wang, W.; Osunkoya, A.O.; Lane, Z.; Partin, A.W.; Epstein, J.I. Residual tumor potentially left behind after local ablation therapy in prostate adenocarcinoma. J Urol. 2008 Jun;179(6):2203-2206; discussion 2206.
Zhao, K.H.; Hernandez, D.J.; Han, M.; Humphreys, E.B.; Mangold, L.A.; Partin, A.W. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score. Urology. 2008 Aug;72(2):396-400.
Antonarakis, E.S.; Heath, E.I.; Walczak, J.R.; Nelson, W.G.; Fedor, H.; De Marzo, A.M.; Zahurak, M.L.; Piantadosi, S.; Dannenberg, A.J.; Gurganus, R.T.; Baker, S.D.; Parnes, H.L.; DeWeese, T.L.; Partin, A.W.; Carducci, M.A. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol. 2009 Oct 20;27(30):4986-4993.
Banez, L.L.; Sun, L.; Trock, B.J.; Han, M.; Partin, A.W.; Aronson, W.J.; Terris, M.K.; Presti, J.C., Jr.; Kane, C.J.; Amling, C.L.; Moul, J.W.; Freedland, S.J. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol. 2009 Aug;182(2):491-496; discussion 496-498.
Brawer, M.K.; Loeb, S.; Partin, A.W.; Yoshimura, N.; Chancellor, M.B.; Roehrborn, C.G.; Assimos, D.G.; Nickel, J.C.; Shuch, B.; Pouliot, F.; Belldegrun, A.S.; Shapiro, E. Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL. Rev Urol. 2009 Spring;11(2):82-107.
Chun, F.K.; de la Taille, A.; van Poppel, H.; Marberger, M.; Stenzl, A.; Mulders, P.F.; Huland, H.; Abbou, C.C.; Stillebroer, A.B.; van Gils, M.P.; Schalken, J.A.; Fradet, Y.; Marks, L.S.; Ellis, W.; Partin, A.W.; Haese, A. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009 Oct;56(4):659-667.
Fujita, K.; Ewing, C.M.; Chan, D.Y.; Mangold, L.A.; Partin, A.W.; Isaacs, W.B.; Pavlovich, C.P. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer. 2009 Feb 1;124(3):664-669.
Hernandez, D.J.; Han, M.; Humphreys, E.B.; Mangold, L.A.; Taneja, S.S.; Childs, S.J.; Bartsch, G.; Partin, A.W. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2009 Mar;103(5):609-614.
Hu, R.; Dunn, T.A.; Wei, S.; Isharwal, S.; Veltri, R.W.; Humphreys, E.; Han, M.; Partin, A.W.; Vessella, R.L.; Isaacs, W.B.; Bova, G.S.; Luo, J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009 Jan 1;69(1):16-22.
Isharwal, S.; Miller, M.C.; Epstein, J.I.; Mangold, L.A.; Humphreys, E.; Partin, A.W.; Veltri, R.W. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction. Urology. 2009 May;73(5):1092-1097.
Jain, A.; McKnight, D.A.; Fisher, L.W.; Humphreys, E.B.; Mangold, L.A.; Partin, A.W.; Fedarko, N.S. Small integrin-binding proteins as serum markers for prostate cancer detection. Clin Cancer Res. 2009 Aug 15;15(16):5199-5207.
Kader, A.K.; Sun, J.; Isaacs, S.D.; Wiley, K.E.; Yan, G.; Kim, S.T.; Fedor, H.; DeMarzo, A.M.; Epstein, J.I.; Walsh, P.C.; Partin, A.W.; Trock, B.; Zheng, S.L.; Xu, J.; Isaacs, W. Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate. 2009 Aug 1;69(11):1195-1205.
Leman, E.S.; Magheli, A.; Cannon, G.W.; Mangold, L.; Partin, A.W.; Getzenberg, R.H. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate. 2009 Aug 1;69(11):1188-1194.
Research Interests
- Bio-Markers for Prostate Disease
More Info
Languages
- English
Memberships
Journal Citations continued:
Armstrong, A.J.; Netto, G.J.; Rudek, M.A.; Halabi, S.; Wood, D.P.; Creel, P.A.; Mundy, K.; Davis, S.L.; Wang, T.; Albadine, R.; Schultz, L.; Partin, A.W.; Jimeno, A.; Fedor, H.; Febbo, P.G.; George, D.J.; Gurganus, R.; De Marzo, A.M.; Carducci, M.A. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-3066.
Guzzo, T.J.; Dluzniewski, P.; Orosco, R.; Platz, E.A.; Partin, A.W.; Han, M. Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology. 2010 Sep;76(3):553-557.
Loeb, S.; Partin, A.W. Open versus minimally invasive radical prostatectomy. Rev Urol. 2010 Winter;12(1):64-65.
Loeb, S.; Partin, A.W. What is the true mortality benefit of prostate-specific antigen screening? Rev Urol. 2010 Winter;12(1):66-67.
Loeb, S.; Partin, A.W. PCA3 Urinary Biomarker for Prostate Cancer. Rev Urol. 2010 Fall;12(4):e205-206.
Loeb, S.; Partin, A.W.; Schaeffer, E.M. Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol. 2010 Winter;12(1):20-24.
Magheli, A.; Gonzalgo, M.L.; Su, L.M.; Guzzo, T.J.; Netto, G.; Humphreys, E.B.; Han, M.; Partin, A.W.; Pavlovich, C.P. Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU Int. 2010 Nov 2.
Sokoll, L.J.; Sanda, M.G.; Feng, Z.; Kagan, J.; Mizrahi, I.A.; Broyles, D.L.; Partin, A.W.; Srivastava, S.; Thompson, I.M.; Wei, J.T.; Zhang, Z.; Chan, D.W. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1193-1200.
Armstrong, A.J.; Netto, G.J.; Rudek, M.A.; Halabi, S.; Wood, D.P.; Creel, P.A.; Mundy, K.; Davis, S.L.; Wang, T.; Albadine, R.; Schultz, L.; Partin, A.W.; Jimeno, A.; Fedor, H.; Febbo, P.G.; George, D.J.; Gurganus, R.; De Marzo, A.M.; Carducci, M.A. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-3066.
Guzzo, T.J.; Dluzniewski, P.; Orosco, R.; Platz, E.A.; Partin, A.W.; Han, M. Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology. 2010 Sep;76(3):553-557.
Loeb, S.; Partin, A.W. Open versus minimally invasive radical prostatectomy. Rev Urol. 2010 Winter;12(1):64-65.
Loeb, S.; Partin, A.W. What is the true mortality benefit of prostate-specific antigen screening? Rev Urol. 2010 Winter;12(1):66-67.
Loeb, S.; Partin, A.W. PCA3 Urinary Biomarker for Prostate Cancer. Rev Urol. 2010 Fall;12(4):e205-206.
Loeb, S.; Partin, A.W.; Schaeffer, E.M. Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol. 2010 Winter;12(1):20-24.
Magheli, A.; Gonzalgo, M.L.; Su, L.M.; Guzzo, T.J.; Netto, G.; Humphreys, E.B.; Han, M.; Partin, A.W.; Pavlovich, C.P. Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching. BJU Int. 2010 Nov 2.
Sokoll, L.J.; Sanda, M.G.; Feng, Z.; Kagan, J.; Mizrahi, I.A.; Broyles, D.L.; Partin, A.W.; Srivastava, S.; Thompson, I.M.; Wei, J.T.; Zhang, Z.; Chan, D.W. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1193-1200.
Clinical Trials
- Prostate Cancer
Additional Resources
Videos and Podcasts
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts